D'Ettorre Gabriella, Forcina Gabriele, Andreotti Mauro, Sarmati Loredana, Palmisano Lucia, Galluzzo Clementina M, Nicastri Emanuele, Mastroianni Claudio M, Vullo Vincenzo, Vella Stefano, Andreoni Massimo
Department of Infectious and Tropical Diseases, La Sapienza University, Rome, Italy.
AIDS. 2002 Sep 27;16(14):1877-85. doi: 10.1097/00002030-200209270-00004.
To study virologic and immunologic factors associated with discordant treatment response in HIV-infected patients receiving highly active antiretroviral therapy (HAART).
Study participants included a total of 27 patients: (a) 10 discordant patients (mean CD4+ cell count, 396.1 x 10 cells/l; mean HIV-RNA, 5.4 log copies/ml); (b) seven responder patients (mean CD4+ cell count, 997.5 x 10 cells/l); and (c) 10 failing patients (mean CD4+ cell count 66.5 x 10 cells/l; mean HIV-RNA, 5.4 log copies/ml).(10) (10)
The HIV-1 isolation rate and biological phenotype, drug resistance genotypic mutations of HIV-1 strains, recall and HIV-1-specific antigen lymphocyte proliferation (LP), and interleukin (IL)-15 production were studied.
Virus isolation was obtained in 30% of discordant patients, and in 100% of failing patients. A higher replication constant was reported in discordant patients. No difference in the number of drug resistance mutations and biological phenotypes of HIV-1 was found in discordant patients with respect to failing patients. Discordant patients developed positive LP responses to and HIV-1 p24. LP in response to, HIV-1 p24 and gp160 was positive in responder patients. No significant LP was found in failing patients. Increased levels of IL-15 after stimulation with lipopolysaccaride (LPS) and were found in both discordant patients and responder patients. Conversely, a strong reduction of IL-15 levels was observed in failing patients.
The present results suggest that decreased virus isolation rate, restoration of both lymphocyte proliferation and IL-15 production are factors involved in the discordant antiretroviral therapy response of HIV-infected patients.
研究接受高效抗逆转录病毒疗法(HAART)的HIV感染患者中与治疗反应不一致相关的病毒学和免疫学因素。
研究参与者共有27名患者:(a)10名反应不一致的患者(平均CD4 +细胞计数,396.1×10个细胞/升;平均HIV-RNA,5.4 log拷贝/毫升);(b)7名有反应的患者(平均CD4 +细胞计数,997.5×10个细胞/升);以及(c)10名治疗失败的患者(平均CD4 +细胞计数66.5×10个细胞/升;平均HIV-RNA,5.4 log拷贝/毫升)。
研究了HIV-1分离率和生物学表型、HIV-1毒株的耐药基因变异、回忆反应和HIV-1特异性抗原淋巴细胞增殖(LP)以及白细胞介素(IL)-15的产生。
30%的反应不一致患者和100%的治疗失败患者分离出病毒。反应不一致的患者报告有更高的复制常数。在反应不一致的患者与治疗失败的患者之间,HIV-1的耐药突变数量和生物学表型没有差异。反应不一致的患者对HIV-1 p24产生阳性LP反应。有反应的患者对HIV-1 p24和gp160的LP反应呈阳性。治疗失败的患者未发现明显的LP反应。用脂多糖(LPS)刺激后,反应不一致的患者和有反应的患者IL-15水平均升高。相反,治疗失败的患者IL-15水平大幅降低。
目前的结果表明,病毒分离率降低、淋巴细胞增殖和IL-15产生的恢复是HIV感染患者抗逆转录病毒治疗反应不一致所涉及的因素。